



CD11b (activation epitope) Monoclonal Antibody (CBRM1/5), eBioscience™

Product Details	
Size	50 μg
Species Reactivity	Human
Published Species	Human
Host/Isotype	Mouse / IgG1, kappa
Class	Monoclonal
Туре	Antibody
Clone	CBRM1/5
Conjugate	Unconjugated
Form	Liquid
Concentration	0.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2
Contains	0.09% sodium azide
Storage conditions	4° C
RRID	AB_467111

Applications	Tested Dilution	Publications
Immunohistochemistry (Paraffin) (IHC (P))	-	1 Publication
Flow Cytometry (Flow)	1 µg/test	16 Publications
Immunoprecipitation (IP)	Assay-Dependent	-
Neutralization (Neu)	Assay-Dependent	2 Publications
Functional Assay (FN)	Assay-Dependent	2 Publications

Product Specific Information

Description: The CBRM1/5 monoclonal antibody reacts with an activation-specific epitope of human Mac-1. CBRM1/5 binds a subset of Mac-1 molecules on neutrophils and monocytes after stimulation with chemoattractants or phorbol esters but does not recognize Mac-1 on resting myeloid cells. Through interactions with its ligands, Mac-1 participates in adhesive cell interactions. The epitope recognized by this mAb localizes to the I domain on the alpha chain of Mac-1 very close to the ligand binding site in a region that is widely exposed. CBRM1/5 blocks Mac-1 dependent adhesion to fibrinogen and ICAM-1 and inhibits chemoattractant-stimulated adhesion of eosinophils to the Intercellular Adhesion Molecule-1 (ICAM-1). It should be noted that low level activation may occur during processing of freshly drawn blood. Therefore the CBRM1.5 antibody may exhibit some binding to Mac-1 in these unstimulated samples. However, higher levels of Mac-1 expression are observed in activated samples when compared to unstimulated cells.

Applications Reported: The CBRM1/5 antibody has been reported for use in flow cytometric analysis, and immunoprecipitation. CBRM1/5 has also been reported in blocking of CD11b function. (Please use Functional Grade purified CBRM1/5, cat. 16-0113, in functional assays.).

Applications Tested: The CBRM1/5 antibody has been tested by flow cytometric analysis of resting and activated normal human peripheral blood cells. This can be used at less than or equal to 1 μ g per test. A test is defined as the amount (μ g) of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of

interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

□ 21 References

Immunohistochemistry (Paraffin) (1)

Blood

Neoangiogenesis contributes to the development of hemophilic synovitis.

"14-0113 was used in Immunohistochemistry to provide evidence of local and systemic angiogenic response in hemophilic subjects with recurrent hemarthroses."

Authors: Acharya SS,Kaplan RN,Macdonald D,Fabiyi OT,DiMichele D,Lyden D

Year 2011

Species Human

Flow Cytometry (16)

FASEB journal: official publication of the Federation of American Societies for Experimental Biology

Year 2022

Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis.

"Published figure using CD11b (activation epitope) monoclonal antibody (Product # 14-0113-81) in Flow Cytometry" Authors: Kraft JD,Blomgran R,Bergström I,Soták M,Clark M,Rani A,Rajan MR,Dalli J,Nyström S,Quiding-Järbrink M, Bromberg J,Skoog P,Börgeson E

Journal of clinical laboratory analysis

Upregulation of CD3 and L-selectin in antigen-specific cytotoxic T lymphocytes by eliminating myeloid-derived suppressor cells with doxorubicin to improve killing efficacy of neuroblastoma cells in vitro.

"Published figure using CD11b (activation epitope) monoclonal antibody (Product # 14-0113-81) in Flow Cytometry" Authors: Xu W.Li S.Li M.Zhou H,Yang X

Year

View more Flow references on thermofisher.com

Neutralization (2)

Arteriosclerosis, thrombosis, and vascular biology

Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype.

"14-0113 was used in Blocking experiments to assess the role of hemostatic components in the recruitment of CD34+cells to sites of injury."

Authors: de Boer HC,Verseyden C,Ulfman LH,Zwaginga JJ,Bot I,Biessen EA,Rabelink TJ,van Zonneveld AJ

Year 2006

Species Human

More applications with references on thermofisher.com

FN (2)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"), No claim of subsiderations regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is immitted to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT.

BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING HE WARRANTIP ENDOSE, OR NON INFRINGEMENT.

BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS OR SURJECT SOLE OPTION. THERE IS NO OBLICATION TO REPAIR, REPLACE OR REFUND FOR THE HE ONO-CONFORMING PRODUCTS, AT SELLER'S SOLE OPTION. THERE IS NO OBLICATION TO REPAIR, REPLACE OR REFUND FOR THE PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED,